AVDL250117P7500
- 0.32
- 0.000.00%
Avadel Pharmaceuticals Newsroom
C-Suite Buy of the Week: Unusual Insider Trading Trends as 2025 Approaches
Several Insiders Invested In Avadel Pharmaceuticals Flagging Positive News
Independent Non-Executive Chairman of the Board of Avadel Pharmaceuticals Picks Up 16% More Stock
Avadel Pharmaceuticals Announces Publication of Findings on Sodium Oxybate
Avadel Pharmaceuticals Presents Results From Social Listening Analysis And Survey Of People With Narcolepsy Uncover Real-Life Challenges With Twice-Nightly Oxybate Therapy
Insider Purchase: Director at $AVDL (AVDL) Buys 3,000 Shares
Avadel Chief Commercial Officer Resigns, Stock Down 14%
UBS Maintains Avadel Pharmaceuticals(AVDL.US) With Buy Rating, Cuts Target Price to $22
US Manufacturing Index Rises To 43, Highest Since 2020
Avadel Pharmaceuticals to Present at the Jefferies London Healthcare Conference
H.C. Wainwright Maintains Avadel Pharmaceuticals(AVDL.US) With Buy Rating, Cuts Target Price to $25
Express News | Avadel Pharmaceuticals PLC : Piper Sandler Raises Target Price to $24 From $23
Avadel Pharmaceuticals Reports Strong Growth With LUMRYZ
Avadel Pharmaceuticals Plc (AVDL) Q3 2024 Earnings Call Transcript Summary
Avadel Pharmaceuticals Plc (AVDL) Q3 2024 Earnings Call Transcript
Express News | Avadel Pharmaceuticals Shares Are Trading Lower. The Company Reported Q3 Financial Results
Avadel Pharmaceuticals | 10-Q: Q3 2024 Earnings Report
Avadel Pharmaceuticals | 8-K: Avadel Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2024 Financial Results
Avadel Pharmaceuticals Price Target Maintained With a $22.00/Share by Needham
Express News | Avadel Pharmaceuticals: Generated $50.0 Mln of Net Product Revenue From Sales of Lumryz in Q3 of 2024